Open AccessExtended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
Author(s) -
Koh Youngil
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1461
Subject(s) - brentuximab vedotin , anaplastic large cell lymphoma , medicine , autologous stem cell transplantation , oncology , transplantation , lymphoma , refractory (planetary science) , stem cell , cd30 , biology , genetics , astrobiology
Key Clinical Message The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical decision‐making, especially in chemorefractory disease.